J&J’s COVID Vaccine Contract With US Bucks Trend Of Increasingly Lucrative Deals
Estimated $14 price per dose for Janssen’s investigational vaccine is first drop in value since Operation Warp Speed started signing contracts. The $1bn purchase order for 100 million doses and earlier $456m for development work is considerably less lucrative than the $2.1bn deal with GSK/Sanofi announced last week, especially since Janssen’s product may end up being a one-dose regimen.
You may also be interested in...
Congress Eyes Vaccine Pricing With Spotlight On Pfizer As COVID Boosters Look More Likely
Senate hearing offers early signals that US lawmakers will be closely watching how COVID-19 vaccine pricing evolves. Biden team pledges to try to make contracting more transparent.
Coronavirus Update: Lilly To Seek EUA For Olumiant
Hot on the heels of positive news from its monoclonal antibody treatment, Lilly aims to seek emergency authorization for anti-inflammatory treatment Olumiant.
J&J COVID Vaccine: Single-Dose Format Will ‘Expedite’ Phase III Trial
Effectiveness can be evaluated more quickly because researchers won’t have to wait for the second dose, company executive notes during briefing on the launch of the Phase III study.